How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

28,700 results for

Parkinsons Disease

by
...
Latest & greatest
Alerts

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

1. Canadian guideline for Parkinson disease

Canadian guideline for Parkinson disease APPENDIX 1: CANADIAN GUIDELINE FOR PARKINSON DISEASE, 2 ND EDITION www.parkinson.ca www.ParkinsonClinicalGuidelines.ca Parkinson-final-E.indd 1 2019-09-05 2:39 PMNote: This full version of the Canadian Guideline for Parkinson Disease has been copyedited to be consistent with the summary article published in CMAJ, but has not been peer reviewed. English printed: 978-1-897490-48-8 English electronic: 978-1-897490-49-5 Parkinson-final-E.indd 2 2019-09-05 2 (...) :39 PMTABLE OF CONTENTS Parkinson-final-E.indd 3 2019-09-05 2:39 PMINTRODUCTION ________________ 6 COMMUNICATION ____________ 12 DIAGNOSIS AND PROGRESSION _______________ 15 TREATMENT _________________ 19 NONMOTOR FEATURES OF PARKINSON DISEASE _______ 28 PALLIATIVE CARE _____________ 36 SUPPLEMENTAL MATERIAL _____ 38 REFERENCES _________________ 51 COMMUNICATION n People with Parkinson disease should be encouraged to participate in choices about their own care. n Communication should be in verbal

2019 CPG Infobase

2. Parkinson?s disease in adults

Parkinson?s disease in adults P Parkinson arkinson’s disease in adults ’s disease in adults NICE guideline Published: 19 July 2017 nice.org.uk/guidance/ng71 © NICE 2019. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and-conditions#notice-of- rights).Y Y our responsibility our responsibility The recommendations in this guideline represent the view of NICE, arrived at after careful consideration of the evidence available. When exercising their judgement (...) . Commissioners and providers have a responsibility to promote an environmentally sustainable health and care system and should assess and reduce the environmental impact of implementing NICE recommendations wherever possible. Parkinson’s disease in adults (NG71) © NICE 2019. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and- conditions#notice-of-rights). Page 2 of 29Contents Contents Overview 4 Who is it for? 4 Recommendations 5 1.1 Communication with people with Parkinson's

2017 National Institute for Health and Clinical Excellence - Clinical Guidelines

3. Parkinson's disease

Parkinson's disease Evidence Maps - Trip Database or use your Google+ account Turning Research Into Practice ALL of these words: Title only Anywhere in the document ANY of these words: Title only Anywhere in the document This EXACT phrase: Title only Anywhere in the document EXCLUDING words: Title only Anywhere in the document Timeframe: to: Combine searches by placing the search numbers in the top search box and pressing the search button. An example search might look like (#1 or #2) and (#3 (...) of known issues . Also read , explaining issues with the system. NOTE : Chrome is the best browser to use! To get started, type a condition/disease into the search box above. Here are some examples to get you started: Building Evidence Map X Axis Alphabetically Risk of bias No. Articles Sample Size Risk of bias any low Minimum sample size Apply Follow us: © 2019 Trip Database Ltd. company number 04316414. Trip is proud to be made in the UK.

2018 Trip Evidence Maps

4. Safinamide (Onstryv) - idiopathic Parkinson's disease

Safinamide (Onstryv) - idiopathic Parkinson's disease Search Page - Drug and Health Product Register Language selection Search and menus Search Search website Search Topics menu You are here: Summary Basis of Decision - - Health Canada Expand all Summary Basis of Decision (SBD) for Contact: Summary Basis of Decision (SBD) documents provide information related to the original authorization of a product. The for is located below. Recent Activity for SBDs written for approved after September 1

2019 Health Canada - Drug and Health Product Register

6. Parkinson's disease

Parkinson's disease Parkinson's disease - Symptoms, diagnosis and treatment | BMJ Best Practice You'll need a subscription to access all of BMJ Best Practice Search  Parkinson's disease Last reviewed: February 2019 Last updated: July 2018 Summary Chronic progressive neurological disorder characterised by motor symptoms of resting tremor, rigidity, bradykinesia, and postural instability. Insidious, often asymmetrical onset. Associated with numerous, often disabling non-motor symptoms. Diagnosis (...) is made clinically. Treatment is symptomatic and involves multidisciplinary care. Definition Idiopathic Parkinson's disease (PD) is a neurodegenerative disorder described in 1817 by the English physician James Parkinson, in a pamphlet entitled, An essay on the shaking palsy. Parkinson J. An essay on the shaking palsy. London: Whittingham and Rowland, 1817. https://archive.org/details/essayonshakingpa00parkuoft http://www.ncbi.nlm.nih.gov/pubmed/11983801?tool=bestpractice.com The cardinal features

2018 BMJ Best Practice

7. Parkinson?s disease

Parkinson?s disease Top results for parkinson's disease - Trip Database or use your Google+ account Turning Research Into Practice ALL of these words: Title only Anywhere in the document ANY of these words: Title only Anywhere in the document This EXACT phrase: Title only Anywhere in the document EXCLUDING words: Title only Anywhere in the document Timeframe: to: Combine searches by placing the search numbers in the top search box and pressing the search button. An example search might look (...) like (#1 or #2) and (#3 or #4) Loading history... Population: Intervention: Comparison: Outcome: Population: Intervention: Latest & greatest articles for parkinson's disease The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials

2018 Trip Latest and Greatest

8. Surgical outcomes of spinal fusion for osteoporotic thoracolumbar vertebral fractures in patients with Parkinson's disease: what is the impact of Parkinson's disease on surgical outcome? (PubMed)

Surgical outcomes of spinal fusion for osteoporotic thoracolumbar vertebral fractures in patients with Parkinson's disease: what is the impact of Parkinson's disease on surgical outcome? To date, there have been little published data on surgical outcomes for patients with PD with thoracolumbar OVF. We conducted a retrospective multicenter study of registry data to investigate the outcomes of fusion surgery for patients with Parkinson's disease (PD) with osteoporotic vertebral fracture (OVF

Full Text available with Trip Pro

2019 BMC Musculoskeletal Disorders

9. Identifying Parkinson's disease and parkinsonism cases using routinely collected healthcare data: A systematic review. (PubMed)

Identifying Parkinson's disease and parkinsonism cases using routinely collected healthcare data: A systematic review. Population-based, prospective studies can provide important insights into Parkinson's disease (PD) and other parkinsonian disorders. Participant follow-up in such studies is often achieved through linkage to routinely collected healthcare datasets. We systematically reviewed the published literature on the accuracy of these datasets for this purpose.We searched four electronic (...) databases for published studies that compared PD and parkinsonism cases identified using routinely collected data to a reference standard. We extracted study characteristics and two accuracy measures: positive predictive value (PPV) and/or sensitivity.We identified 18 articles, resulting in 27 measures of PPV and 14 of sensitivity. For PD, PPV ranged from 56-90% in hospital datasets, 53-87% in prescription datasets, 81-90% in primary care datasets and was 67% in mortality datasets. Combining diagnostic

Full Text available with Trip Pro

2019 PLoS ONE

10. Clinical effectiveness and cost-effectiveness of physiotherapy and occupational therapy versus no therapy in mild to moderate Parkinson s disease: a large pragmatic randomised controlled trial (PD REHAB) (PubMed)

Clinical effectiveness and cost-effectiveness of physiotherapy and occupational therapy versus no therapy in mild to moderate Parkinson s disease: a large pragmatic randomised controlled trial (PD REHAB) Clinical effectiveness and cost-effectiveness of physiotherapy and occupational therapy versus no therapy in mild to moderate Parkinson's disease: a large pragmatic randomised controlled trial(PD REHAB) Journals Library An error occurred retrieving content to display, please try again

Full Text available with Trip Pro

2016 NIHR HTA programme

11. Early predictors of mortality in parkinsonism and Parkinson disease: A population-based study

Early predictors of mortality in parkinsonism and Parkinson disease: A population-based study To examine mortality and associated risk factors, including possible effects of mild cognitive impairment, imaging, and CSF abnormalities, in a community-based population with incident parkinsonism and Parkinson disease.One hundred eighty-two patients with new-onset, idiopathic parkinsonism were diagnosed from January 2004 through April 2009, in a catchment area of 142,000 inhabitants in Sweden (...) with atypical parkinsonism (multiple system atrophy or progressive supranuclear palsy) had the highest mortality. In early Parkinson disease, a mild cognitive impairment diagnosis, freezing of gait, hyposmia, reduced dopamine transporter activity in the caudate, and elevated leukocytes in the CSF were significantly associated with shorter survival.Although patients presenting with idiopathic parkinsonism have reduced survival, the survival is highly dependent on the type and characteristics

Full Text available with Trip Pro

2018 EvidenceUpdates

12. Clinical Determinants of Parkinson's Disease‐associated Pain Using the King's Parkinson's Disease Pain Scale (PubMed)

Clinical Determinants of Parkinson's Disease‐associated Pain Using the King's Parkinson's Disease Pain Scale Pain is a frequent feature in Parkinson's disease (PD). Current knowledge on pain and its associated factors in PD has been obtained using nondisease-specific tools. Recently, the King's Parkinson's Disease Pain Scale (KPPS) was published as the first disease-specific scale. The aim of this study was to assess PD-associated pain and its main determinants using the KPPS.A cross (...) -sectional study was carried out. Consecutive patients with PD were recruited from a movement disorders clinic. Clinical and demographical data were collected. The KPPS, the Movement Disorders Society Unified Parkinson's Disease Rating Scale, and the Non-Motor Symptoms Scale were used to assess all participants.In total, 314 patients were included. Overall, 88.6% of the sample reported at least 1 type of pain. The mean ± standard KPPS score was 18.8 ± 19.5. Factors associated with higher KPSS scores were

Full Text available with Trip Pro

2017 Movement disorders clinical practice

13. Progression of MDS‐UPDRS Scores Over Five Years in De Novo Parkinson Disease from the Parkinson's Progression Markers Initiative Cohort (PubMed)

Progression of MDS‐UPDRS Scores Over Five Years in De Novo Parkinson Disease from the Parkinson's Progression Markers Initiative Cohort The Movement Disorder Society Unified Parkinson Disease Rating Scale (MDS-UDPRS) is a commonly used tool to measure Parkinson disease (PD) progression. Longitudinal changes in MDS-UPDRS scores in de novo PD have not been established.Determine progression rates of MDS-UPDRS scores in de novo PD.362 participants from the Parkinson's Progression Markers (...) in clinical monitoring and provide comparative data for detection of disease modification in treatment trials.

Full Text available with Trip Pro

2017 Movement disorders clinical practice

14. Virtual reality for rehabilitation in Parkinson's disease. (PubMed)

Virtual reality for rehabilitation in Parkinson's disease. Parkinson's disease (PD) is a neurodegenerative disorder that is best managed by a combination of medication and regular physiotherapy. In this context, virtual reality (VR) technology is proposed as a new rehabilitation tool with a possible added value over traditional physiotherapy approaches. It potentially optimises motor learning in a safe environment, and by replicating real-life scenarios could help improve functional activities

Full Text available with Trip Pro

2016 Cochrane

15. Transcranial direct current stimulation (tDCS) for idiopathic Parkinson's disease. (PubMed)

Transcranial direct current stimulation (tDCS) for idiopathic Parkinson's disease. Idiopathic Parkinson's disease (IPD) is a neurodegenerative disorder, with the severity of the disability usually increasing with disease duration. IPD affects patients' health-related quality of life, disability, and impairment. Current rehabilitation approaches have limited effectiveness in improving outcomes in patients with IPD, but a possible adjunct to rehabilitation might be non-invasive brain stimulation (...) ) and extracted data (BE and JM). If necessary, we contacted study authors to ask for additional information. We collected information on dropouts and adverse events from the trial reports.We included six trials with a total of 137 participants. We found two studies with 45 participants examining the effects of tDCS compared to control (sham tDCS) on our primary outcome measure, impairment, as measured by the Unified Parkinson's Disease Rating Scale (UPDRS). There was very low quality evidence for no effect

Full Text available with Trip Pro

2016 Cochrane

16. Opicapone (Parkinson disease): Addendum to Commission A16-61

Opicapone (Parkinson disease): Addendum to Commission A16-61 Opicapon (Parkinsonkrankheit): Addendum zum Auftrag A16-61; Auftrag A17-04 [Opicapone (Parkinson disease): Addendum to Commission A16-61] Opicapon (Parkinsonkrankheit): Addendum zum Auftrag A16-61; Auftrag A17-04 [Opicapone (Parkinson disease): Addendum to Commission A16-61] Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen Record Status This is a bibliographic record of a published health technology assessment from (...) a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen. Opicapon (Parkinsonkrankheit): Addendum zum Auftrag A16-61; Auftrag A17-04. [Opicapone (Parkinson disease): Addendum to Commission A16-61] Cologne: Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG). IQWiG-Berichte 489. 2017 Final publication URL Indexing Status Subject indexing assigned by CRD MeSH

2017 Health Technology Assessment (HTA) Database.

17. ‘Low dose’ physiotherapy and occupational therapy found ineffective for people with mild to moderate Parkinson’s disease

‘Low dose’ physiotherapy and occupational therapy found ineffective for people with mild to moderate Parkinson’s disease ‘Low dose’ physiotherapy and occupational therapy found ineffective for people with mild to moderate Parkinson’s disease Discover Portal Discover Portal ‘Low dose’ physiotherapy and occupational therapy found ineffective for people with mild to moderate Parkinson’s disease Published on 23 March 2016 doi: Physiotherapy and occupational therapy do not help people with mild (...) to moderate Parkinson’s disease to lead more independent lives. This NIHR-funded randomised controlled trial of adults with Parkinson’s disease did not find any difference between the therapy group and a no-therapy control group at up to 15 months in any of the four measures of activities of daily living: mobility, kitchen activities, domestic tasks or leisure activities. The average ‘dose’ of the therapies was four sessions of 58 minutes over eight weeks for both therapies combined. The number

2019 NIHR Dissemination Centre

18. Path Finder for freezing of gait in people with Parkinson?s disease

Path Finder for freezing of gait in people with Parkinson?s disease P Path Finder for freezing of gait in people with ath Finder for freezing of gait in people with P Parkinson arkinson’s disease ’s disease Medtech innovation briefing Published: 25 January 2019 nice.org.uk/guidance/mib170 pathways Summary Summary The technology technology described in this briefing is Path Finder laser shoe attachment. It is used as a walking aid and is designed to help prevent freezing of gait in people (...) with Parkinson's disease. The inno innovativ vative aspects e aspects are that it is currently the only hands-free visual-cueing device for people with Parkinson's disease available in the UK. The intended place in ther place in therap apy y would be in place of other visual-cue walking aids but together with a reduced number of physiotherapy sessions, depending on the individuals' disease stage and personal preference. It would be used by the patient in their home or in the physiotherapy clinic. It may also

2019 National Institute for Health and Clinical Excellence - Advice

19. Parkinson's disease in adults.

Parkinson's disease in adults. Parkinson's disease in adults. | National Guideline Clearinghouse success fail JUN 09 2017 2018 2019 14 Apr 2018 - 12 Jul 2018 COLLECTED BY Organization: Formed in 2009, the Archive Team (not to be confused with the archive.org Archive-It Team) is a rogue archivist collective dedicated to saving copies of rapidly dying or deleted websites for the sake of history and digital heritage. The group is 100% composed of volunteers and interested parties, and has expanded (...) ? The AHRQ National Guideline Clearinghouse (NGC, guideline.gov) Web site will not be available after July 16, 2018 because federal funding through AHRQ will no longer be available to support the NGC as of that date. For additional information, read our . Guideline Summary NGC:011245 2017 Jul 19 NEATS Assessment Parkinson's disease in adults. National Institute for Health and Care Excellence (NICE). Parkinson's disease in adults. London (UK): National Institute for Health and Care Excellence (NICE); 2017

2017 National Guideline Clearinghouse (partial archive)

20. Serum NFL discriminates Parkinson disease from atypical parkinsonisms. (PubMed)

Serum NFL discriminates Parkinson disease from atypical parkinsonisms. To investigate the diagnostic value of serum neurofilament light chain (NFL) in patients with clear signs of parkinsonism but whose specific diagnosis was yet uncertain.Serum samples were collected from patients with clear signs of parkinsonism but with uncertain diagnosis at the inclusion. Clinical diagnoses of Parkinson disease (PD) and atypical parkinsonism disorders (APDs) were established after 3 years of follow-up

2019 Neurology

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>